Taysha Gene Therapies Inc., a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), has announced executive leadership changes effective immediately.   Taysha’s Chair of the Board of Directors, Sean P. Nolan, has been appointed Chief Executive Officer, succeeding RA Session II, who has resigned from his operating role, but will continue to serve on the c...